Eli Lilly 2015 Annual Report Download - page 143

Download and view the complete annual report

Please find page 143 of the 2015 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 186

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184
  • 185
  • 186

P27
Principal Holders of Stock
To the best of the company’s knowledge, the only beneficial owners of more than 5 percent of the outstanding
shares of the company’s common stock, as of December 31, 2015, are the shareholders listed below:
Name and Address
Number of Shares
Beneficially Owned Percent of Class
Lilly Endowment Inc. (the Endowment)
2801 North Meridian Street
Indianapolis, Indiana 46208
127,860,804 11.5%
BlackRock, Inc.
55 East 52nd Street
New York, New York 10055
66,007,964 6.0%
The Vanguard Group
100 Vanguard Blvd.
Malvern, PA 19355
59,913,179 5.4%
PRIMECAP Management Company
225 South Lake Ave., #400
Pasadena, CA 91101
57,654,392 5.2%
The Endowment has sole voting and sole dispositive power with respect to all of its shares. The Board of
Directors of the Endowment is composed of N. Clay Robbins, chairman, president & chief executive officer;
Mary K. Lisher; William G. Enright; Daniel P. Carmichael; Charles E. Golden; Eli Lilly II; David N. Shane; Craig
Dykstra; and Jennett M. Hill.
BlackRock, Inc. provides investment management services for various clients. It has sole voting power with
respect to 57,088,447 of its shares and sole dispositive power with respect to 65,974,281 of its shares.
The Vanguard Group provides investment management services for various clients. It has sole voting power
with respect to 1,832,006 of its shares and sole dispositive power with respect to 57,973,673 of its shares.
PRIMECAP Management Company acts as investment advisor to various clients. It has sole voting power
with respect to 11,365,505 shares and sole dispositive power with respect to all of its shares.
Compensation
Item 2. Advisory Vote on Compensation Paid to Named
Executive Officers
Section 14A of the Securities Exchange Act of 1934 provides the company's shareholders with the opportunity
to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed
in the proxy statement. As described in the CD&A section below, our compensation philosophy is designed to
attract and retain highly-talented individuals and motivate them to create long-term shareholder value by
achieving top-tier corporate performance while embracing the company’s values of integrity, excellence, and
respect for people.
The Compensation Committee and the Board of Directors believe that our executive compensation aligns well
with our philosophy and with corporate performance. Executive compensation is an important matter for our
shareholders. We routinely review our compensation practices and engage in ongoing dialog with our
shareholders in order to ensure our practices are aligned with stakeholder interests and reflect best practices.
We request shareholder approval, on an advisory basis, of the compensation of the company’s named
executive officers as disclosed in this proxy statement. As an advisory vote, this proposal is not binding on the
company. However, the Compensation Committee values input from shareholders and will consider the
outcome of the vote when making future executive compensation decisions.
Compensation